Business Description
Rallybio Corp
ISIN : US75120L2097
Total Employee Number:
9Description
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 303.86 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 4.97 | |||||
Beneish M-Score | -2.28 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 29.9 | |||||
3-Year EPS without NRI Growth Rate | 54.4 | |||||
3-Year FCF Growth Rate | 28.4 | |||||
3-Year Book Growth Rate | -32.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.92 | |||||
Quick Ratio | 12.92 | |||||
Cash Ratio | 11.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.8 | |||||
Shareholder Yield % | 0.06 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -3744.41 | |||||
Net Margin % | -911.07 | |||||
EBITDA Margin % | -3736.6 | |||||
FCF Margin % | -3215.15 | |||||
OCF Margin % | -3215.15 | |||||
ROE % | -14.41 | |||||
ROA % | -13.32 | |||||
ROIC % | -651.69 | |||||
3-Year ROIIC % | 29260.5 | |||||
ROC (Joel Greenblatt) % | -1822.08 | |||||
ROCE % | -59.16 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 106.58 | |||||
PB Ratio | 1.7 | |||||
Price-to-Tangible-Book | 1.71 | |||||
EV-to-EBIT | -1.22 | |||||
EV-to-EBITDA | -1.23 | |||||
EV-to-Revenue | 45.84 | |||||
EV-to-FCF | -1.43 | |||||
| Price-to-Net-Current-Asset-Value | 1.74 | |||||
| Price-to-Net-Cash | 2.01 | |||||
Earnings Yield (Greenblatt) % | -81.97 | |||||
FCF Yield % | -32.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rallybio Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.858 | ||
| EPS (TTM) (€) | -1.37 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 13.5 - 14.4 | ||
| Shares Outstanding (Mil) | 5.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rallybio Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rallybio Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 102 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 11 days | ||
| General meeting for 2026 | 2026-07-29 | In 2 days | ||
| First quarter earnings results for 2026 | 2026-05-13 | -- | ||
| Annual report for 2025 | 2026-03-16 | -- | ||
| Merger Between Rallybio Corporation and Candid Therapeutics | 2026-03-02 08:30 | -- | ||
| Third quarter earnings results for 2025 | 2025-11-06 | -- | ||
| Second quarter earnings results for 2025 | 2025-08-07 | -- | ||
| General meeting for 2025 | 2025-05-13 09:00 | -- | ||
| First quarter earnings results for 2025 | 2025-05-08 08:00 | -- |
Show
Entries
Rallybio Corp Frequently Asked Questions
What is Rallybio Corp(FRA:33M0)'s stock price today?
The current price of FRA:33M0 is €13.90. The 52 week high of FRA:33M0 is €14.40 and 52 week low is €13.50.
When is next earnings date of Rallybio Corp(FRA:33M0)?
The next earnings date of Rallybio Corp(FRA:33M0) is 2026-08-07 Est..
Does Rallybio Corp(FRA:33M0) pay dividends? If so, how much?
Rallybio Corp(FRA:33M0) does not pay dividend.
Press Release
Articles on Rallybio Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers